Stock Track | ANI Pharmaceuticals Soars 5% as Analysts Boost Price Targets Post Strong Q2 Earnings

Stock Track

Aug 11

Shares of ANI Pharmaceuticals (ANIP) are soaring 5.09% in Monday's intraday trading session, buoyed by a wave of analyst upgrades following the company's strong second-quarter earnings report. The pharmaceutical firm's stock is attracting investor attention as multiple financial institutions revise their outlook on the company's potential.

Leading the optimistic sentiment, Raymond James has significantly raised its price target for ANI Pharmaceuticals to $99 from $86. Similarly, Truist Securities has upped its target to $77 from $65, although it maintains a Hold rating on the stock. These upgrades reflect growing confidence in ANI Pharmaceuticals' business performance and future prospects.

The positive momentum is further reinforced by the broader analyst consensus. According to FactSet, ANI Pharmaceuticals currently holds an average rating of Buy, with a mean price target of $90.50. This bullish outlook suggests that despite the day's substantial gains, analysts see potential for further upside in ANIP's stock price. Investors appear to be responding positively to these optimistic projections, driving the stock's impressive intraday rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104873795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104873795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104873795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104873795","market":"hk","top_or_hot":-1,"title":"Stock Track | ANI Pharmaceuticals Soars 5% as Analysts Boost Price Targets Post Strong Q2 Earnings","media":"Stock Track","content":"<p>Shares of ANI Pharmaceuticals (ANIP) are soaring 5.09% in Monday's intraday trading session, buoyed by a wave of analyst upgrades following the company's strong second-quarter earnings report. The pharmaceutical firm's stock is attracting investor attention as multiple financial institutions revise their outlook on the company's potential.</p>\n\n<p>Leading the optimistic sentiment, Raymond James has significantly raised its price target for ANI Pharmaceuticals to $99 from $86. Similarly, Truist Securities has upped its target to $77 from $65, although it maintains a Hold rating on the stock. These upgrades reflect growing confidence in ANI Pharmaceuticals' business performance and future prospects.</p>\n\n<p>The positive momentum is further reinforced by the broader analyst consensus. According to FactSet, ANI Pharmaceuticals currently holds an average rating of Buy, with a mean price target of $90.50. This bullish outlook suggests that despite the day's substantial gains, analysts see potential for further upside in ANIP's stock price. Investors appear to be responding positively to these optimistic projections, driving the stock's impressive intraday rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ANI Pharmaceuticals Soars 5% as Analysts Boost Price Targets Post Strong Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ANI Pharmaceuticals Soars 5% as Analysts Boost Price Targets Post Strong Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-11 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of ANI Pharmaceuticals (ANIP) are soaring 5.09% in Monday's intraday trading session, buoyed by a wave of analyst upgrades following the company's strong second-quarter earnings report. The pharmaceutical firm's stock is attracting investor attention as multiple financial institutions revise their outlook on the company's potential.</p>\n\n<p>Leading the optimistic sentiment, Raymond James has significantly raised its price target for ANI Pharmaceuticals to $99 from $86. Similarly, Truist Securities has upped its target to $77 from $65, although it maintains a Hold rating on the stock. These upgrades reflect growing confidence in ANI Pharmaceuticals' business performance and future prospects.</p>\n\n<p>The positive momentum is further reinforced by the broader analyst consensus. According to FactSet, ANI Pharmaceuticals currently holds an average rating of Buy, with a mean price target of $90.50. This bullish outlook suggests that despite the day's substantial gains, analysts see potential for further upside in ANIP's stock price. Investors appear to be responding positively to these optimistic projections, driving the stock's impressive intraday rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1104873795","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104873795","pubTimestamp":1754921312,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ANI Pharmaceuticals (ANIP) are soaring 5.09% in Monday's intraday trading session, buoyed by a wave of analyst upgrades following the company's strong second-quarter earnings report. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"股票追踪|ANI Pharmaceuticals飙升5%，分析师在第二季度强劲盈利后上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1},"content_text":"Shares of ANI Pharmaceuticals (ANIP) are soaring 5.09% in Monday's intraday trading session, buoyed by a wave of analyst upgrades following the company's strong second-quarter earnings report. The pharmaceutical firm's stock is attracting investor attention as multiple financial institutions revise their outlook on the company's potential.\nLeading the optimistic sentiment, Raymond James has significantly raised its price target for ANI Pharmaceuticals to $99 from $86. Similarly, Truist Securities has upped its target to $77 from $65, although it maintains a Hold rating on the stock. These upgrades reflect growing confidence in ANI Pharmaceuticals' business performance and future prospects.\nThe positive momentum is further reinforced by the broader analyst consensus. According to FactSet, ANI Pharmaceuticals currently holds an average rating of Buy, with a mean price target of $90.50. This bullish outlook suggests that despite the day's substantial gains, analysts see potential for further upside in ANIP's stock price. Investors appear to be responding positively to these optimistic projections, driving the stock's impressive intraday rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}